Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck KGaA
NY AG has ‘no comment’ on whether criminal charges will be pursued against company executives; NC AG predicts ‘north of 40 states’ expected to accept settlement and would then need to convince municipalities to come on board. States with ongoing litigation against manufacturers may opt for jury trial instead.
The biotech giant signed a commercial agreement with bioelectronics company Innervia, and the two will work collaboratively on vagus nerve stimulating technologies.
Merck unveiled event-free survival results for Keytruda in triple-negative breast cancer following failure earlier this year to gain approval on a surrogate endpoint.
After four years of litigation, Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan establish a monopoly for the EpiPen autoinjector device.
- Research, Analytical Equipment & Supplies
- Drug Delivery
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Acadiana Ventures Inc.
- Allergopharma Joachim Ganzer KG
- AmpTec GmbH
- EMD Pharmaceuticals
- Grzybowski Scientific Inventions (GSI)
- Intermolecular Inc
- JRH Biosciences
- Merck Hoei Ltd.
- Ormet Circuts Inc.
- EMD Serono, Inc.
- Versum Materials, Inc.